NasdaqCM:EXASBiotechs
Exact Sciences (EXAS) Loss Rebound In Q4 Challenges Profitability Progress Narrative
Exact Sciences (EXAS) just reported its FY 2025 numbers with fourth quarter revenue of US$878.4 million, a basic EPS loss of US$0.45 and net income loss of US$86.0 million, while on a trailing twelve month basis revenue came in at about US$3.2 billion with a basic EPS loss of US$1.10 and a net income loss of US$207.9 million. The company has seen quarterly revenue move from US$713.4 million in Q4 2024 to US$878.4 million in Q4 2025, with basic EPS losses over that span ranging from US$4.67 to...